List of OrphAI Therapeutics patents

List of OrphAI Therapeutics patents

List of Exabeam patents

List of IronPort Systems patents

List of Quickie Manufacturing patents

List of patents in the Consumer packaged goods (CPG) industry

List of companies in GOVTOR's investment portfolio

Patents where

Current Assignee

Name

is

OrphAI Therapeutics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11491143 Inhalable rapamycin formulation for the treatment of pulmonary hypertension	Patent 11491143 was granted and assigned to AI Therapeutics on November, 2022 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	11491143	November 8, 2022
	‌ US Patent 11744797 Rapamycin for the treatment of lymphangioleiomyomatosis	Patent 11744797 was granted and assigned to AI Therapeutics on September, 2023 by the United States Patent and Trademark Office.		OrphAI Therapeutics		United States Patent and Trademark Office	11744797	September 5, 2023
	‌ US Patent 10307371 Rapamycin for the treatment of lymphangioleiomyomatosis	Patent 10307371 was granted and assigned to AI Therapeutics on June, 2019 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	10307371	June 4, 2019
	‌ US Patent 11103449 Inhalable rapamycin formulation for treating age-related conditions	Patent 11103449 was granted and assigned to AI Therapeutics on August, 2021 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	11103449	August 31, 2021
	‌ US Patent 11266654 Apilimod compositions and methods for using same	Patent 11266654 was granted and assigned to AI Therapeutics on March, 2022 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	11266654	March 8, 2022
	‌ US Patent 10307370 Rapamycin for the treatment of lymphangioleiomyomatosis	Patent 10307370 was granted and assigned to AI Therapeutics on June, 2019 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	10307370	June 4, 2019
	‌ US Patent 10179135 Apilimod compositions and methods for using same	Patent 10179135 was granted and assigned to AI Therapeutics on January, 2019 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	10179135	January 15, 2019
	‌ US Patent 10350213 Methods for treating cancer using apilimod	Patent 10350213 was granted and assigned to AI Therapeutics on July, 2019 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	10350213	July 16, 2019
	‌ US Patent 11123289 Rapamycin for the treatment of lymphangioleiomyomatosis	Patent 11123289 was granted and assigned to AI Therapeutics on September, 2021 by the United States Patent and Trademark Office.		OrphAI Therapeutics		United States Patent and Trademark Office	11123289	September 21, 2021
	‌ US Patent 11166944 Apilimod compositions and methods for using same in the treatment of renal cancer	Patent 11166944 was granted and assigned to AI Therapeutics on November, 2021 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	11166944	November 9, 2021
	‌ US Patent 11439649 Combination therapy with apilimod and glutamatergic agents	Patent 11439649 was granted and assigned to OrphAI Therapeutics on September, 2022 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	11439649	September 13, 2022
	‌ US Patent 10206910 Apilimod for use in the treatment of renal cancer	Patent 10206910 was granted and assigned to AI Therapeutics on February, 2019 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	10206910	February 19, 2019
	‌ US Patent 10765682 Apilimod for use in the treatment of melanoma	Patent 10765682 was granted and assigned to AI Therapeutics on September, 2020 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	10765682	September 8, 2020
	‌ US Patent 10751345 Combination therapy with apilimod and glutamatergic agents	Patent 10751345 was granted and assigned to OrphAI Therapeutics on August, 2020 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	10751345	August 25, 2020
	‌ US Patent 10729694 Anti-viral compositions containing PIKfyve inhibitors and use thereof	Patent 10729694 was granted and assigned to AI Therapeutics on August, 2020 by the United States Patent and Trademark Office.	OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	10729694	August 4, 2020
	‌ US Patent 10702534 Compositions and methods relating to the radioprotective effects of apilimod		OrphAI Therapeutics	OrphAI Therapeutics		United States Patent and Trademark Office	10702534	July 7, 2020

16 results

0 selected

16 results

0 selected